HC Wainwright & Co. Reiterates Buy on Scribe Therapeutics, Maintains $60 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Scribe Therapeutics (NASDAQ:SCTX) with a Buy and maintains $60 price target.